Select Advances in Infectious Disease Chemotherapy: Review for Emergency Department Practitioners
- 46 Downloads
Purpose of Review
We provide an overview of new chemotherapy agents for the treatment of bacterial, viral, fungal, and parasitic infections with indications, contraindications, and side effects for each. Some of them have been restricted for use only by subspecialists, possibly limiting emergency physicians’ comfort with prescribing these medications. We also review some new and promising agents that have not been approved by the Food and Drug Administration as of this writing.
As new antibiotics are approved and widely used, postmarketing surveys uncover important findings with respect to the drugs’ efficacy, drug interactions, and side effects. The fact that these agents are intended to definitively cure diseases which may in some cases prove lethal makes it imperative for clinicians to stay abreast of developments in infectious disease. Conversely, the fact that these medications are prescribed for limited periods of time in order to prove curative and to prevent the development of resistance poses financial challenges to the pharmaceutical industry.
This article provides the emergency department clinicians with a summary of novel antimicrobials and their relevance to the practice of clinical and emergency medicine, as well as highlighting recent research into the topic.
KeywordsAntimicrobials Emergency care Novel antibiotics Antibiotic resistance Antivirals Antifungals
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance
- 1.•• Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J Antibiot. 2016;69:73–88. Gives rationale for why pharmaceutical companies may be lagging in funding for newer antibacterials. CrossRefPubMedGoogle Scholar
- 4.Falzon, D., Schünemann, H. J. (2017). World Health Organization treatment guidelines for drug-resistant tuberculosis 2016 Update Eur Respir J, 49, 3.Google Scholar
- 20.Laidman J. Despite growing crisis, few new antibiotics are in pipeline. Medscape Med News. 2013Google Scholar
- 22.Delafloxacin: a new fluoroquinolone antibiotic. Med Lett Drugs Ther. 2018;60(1543):49–51.Google Scholar
- 23.•• Drugs for common bacterial infections in adults. Med Lett Drugs Ther. 2017;59(1532):171–7. This is an overview of treatment for specific bacterial diseases. This is an authoritative publication with recommendations made generally by panels held in high esteem. Google Scholar
- 24.Available at http://www.centerwatch.com/drug-information/fda-approved -Drugs Accessed 25 April 2018.